Gaudium IVF adopts FY26 financials in first AGM as listed firm
- Adopted audited standalone and consolidated financial statements for FY26
- Approved revision of remuneration for Whole-Time Director Dr. Peeyush Khanna
- Ratified remuneration for Chairperson and MD Dr. Manika Khanna
- Appointed M/s. Suresh Nainwal & Company as Secretarial Auditors for five years
- Re-appointed Mr. Vishad Khanna as Non-Executive Director
*this image is generated using AI for illustrative purposes only.
Gaudium IVF and Women Health Limited held its 11th Annual General Meeting on September 28, 2026, marking its first such gathering since listing. Members adopted the audited standalone and consolidated financial statements for FY26 and approved key governance resolutions.
The meeting was conducted via Video Conferencing/Other Audio-Visual Means (VC/OAVM) from the registered office in New Delhi. Dr. Manika Khanna, Chairperson and Managing Director, chaired the proceedings, highlighting the company's transition from a clinician-led practice to a listed institutional healthcare platform following its IPO in February 2026.
Financial performance highlights
Mr. Rakesh Kumar Sharma, Chief Financial Officer, briefed members on the company's financial health for the fiscal year ended March 31, 2026. He reported growth in consolidated revenue from operations, EBITDA, profit after tax, earnings per share, and return on equity. The CFO also emphasized the company's debt-light balance sheet structure.
Governance and appointments
The shareholders passed several ordinary and special resolutions regarding board composition and executive compensation. Mr. Suresh Marpu, Independent Director, chaired the session for items involving interested parties to ensure compliance with Secretarial Standards.
| Item | Resolution | Type |
|---|---|---|
| 1 | Adoption of audited standalone and consolidated financial statements for FY26 | Ordinary |
| 2 | Re-appointment of Mr. Vishad Khanna as Non-Executive Director | Ordinary |
| 3 | Revision of remuneration for Dr. Peeyush Khanna (Whole-Time Director) | Special |
| 4 | Ratification of remuneration for Dr. Manika Khanna (Chairperson and MD) | Special |
| 5 | Appointment of M/s. Suresh Nainwal & Company as Secretarial Auditors for five years | Ordinary |
Strategic updates
During the address, the management outlined progress since the balance sheet date. Key developments included the deployment of AI-enabled tools SiD and ERICA in partnership with IVF 2.0, the commencement of hub roll-outs, and expansion of international reach. The company also highlighted the scale of its hub-and-spoke network and clinical quality metrics.
What the numbers show
The disclosure of a "debt-light balance sheet" alongside reported growth in EBITDA and PAT suggests the company is prioritizing capital efficiency and self-funded growth in its initial phase as a listed entity. This financial posture provides flexibility for the announced capital-intensive initiatives, such as the AI tool deployment and network expansion, without immediate reliance on external leverage.
Historical Stock Returns for Gaudium IVF & Women Health
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.62% | -3.46% | -3.19% | +42.31% | +39.80% | +39.80% |
How will the deployment of AI-enabled tools SiD and ERICA impact Gaudium IVF's patient acquisition costs and success rates in the next fiscal year?
What specific capital allocation strategies will the company employ to fund its hub-and-spoke network expansion while maintaining its debt-light balance sheet?
How does the company plan to navigate regulatory challenges in international markets as it scales its global reach?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
